New drug combo aims to keep bladder cancer from coming back
NCT ID NCT07207824
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive either the drug combo or BCG alone, and researchers will track how long they stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200230, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood or urine test spot bladder cancer earlier?
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Could a common vitamin restore immunotherapy power after antibiotics?
- Could less be more? bladder cancer trial tests stopping immunotherapy after tumors vanish
- Could bladder bacteria trigger cancer? new study investigates